CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
pegaptanib sodium (Macugen)drug
Likely dose
pegaptanib sodium (Macugen) 0.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00406107
NCT00406107Phase 4Completed
CompareCT.gov

Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

Palmetto Retina Center, LLC·interventional·Posted Dec 4, 2006·Updated Sep 12, 2014

In Brief

A Phase 4 clinical trial evaluating pegaptanib sodium (Macugen) for Branch Retinal Vein Occlusion. Completed, enrolled 20 participants across 3 sites.

Detailed Summary

The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBranch Retinal Vein Occlusion
CountriesUnited States
CollaboratorsPfizer, Eyetech Pharmaceuticals

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 4, 2006
Enrollment StartJan 1, 2006
Primary CompletionDec 1, 2007
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.6 years ago

Interventions

pegaptanib sodium (Macugen)drug

Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.